Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Ulcerative Colitis – Unmet Need – Unmet Need – Moderate to Severe Ulcerative Colitis (US/EU)
TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine ’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s Entyvio), a JAK inhibitor (Pfizer’s Xeljanz), and an IL-12/23 inhibitor…
Ulcerative Colitis | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2025
Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Children with UC have a more-complicated disease course compared with adult patients…
Ulcerative Colitis | Treatment Algorithms: Claims Data Analysis | Adult | US | 2024
Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Treatment typically begins with conventional agents (e.g., 5-aminosalicylic acids [5-ASAs])…
Ulcerative Colitis | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2024
Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Children with UC have a more-complicated disease course compared with adult patients…
Ulcerative Colitis – Current Treatment – Current Treatment: Physician Insights – Ulcerative Colitis (EU5)
Many well-established therapies are available to treat ulcerative colitis (UC) in the EU5. TNF-alpha inhibitors (Janssen’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s Entyvio), and…
Ulcerative Colitis | Treatment Algorithms: Claims Data Analysis | Adult | US | 2023
Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Treatment typically begins with conventional agents (e.g., 5-aminosalicylic acids [5-ASAs])…
